ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

EDIT Editas Medicine Inc

5.10
0.03 (0.59%)
19 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Editas Medicine Inc NASDAQ:EDIT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.03 0.59% 5.10 5.01 5.12 5.31 4.965 5.29 3,576,435 00:50:01

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

26/07/2023 12:00pm

GlobeNewswire Inc.


Editas Medicine (NASDAQ:EDIT)
Historical Stock Chart


From Jun 2023 to Jun 2024

Click Here for more Editas Medicine Charts.

Editas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage genome editing company, today announced that it will host a conference call and webcast on Wednesday, August 2, 2023, at 8:00 a.m. ET to discuss results for the second quarter 2023 and to provide a corporate update.

To access the conference call:

  • U.S. callers should dial +1-877-407-0989 and international callers should dial +1-201-389-0921 approximately five minutes before the call begins.
  • Participants should ask to be connected to the Editas Medicine Earnings Conference Call.

The conference call will also be webcast and can be accessed from the “Investors” section of the Editas Medicine website at https://www.editasmedicine.com. A replay will be available at the same site approximately one hour after the completion of the call.

About Editas MedicineAs a clinical-stage genome editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and Cas9 genome editing systems into a robust pipeline of treatments for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision genomic medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com.

Media and Investor Contact:
Cristi Barnett
(617) 401-0113
cristi.barnett@editasmed.com

1 Year Editas Medicine Chart

1 Year Editas Medicine Chart

1 Month Editas Medicine Chart

1 Month Editas Medicine Chart

Your Recent History

Delayed Upgrade Clock